Evidence map›Paper›PMID 31889876›Full record

ArticleSaudi journal of biological sciences2020

Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia.

Niyaz Ahmad, Rizwan Ahmad, Farhan Jalees Ahmad, Wasim Ahmad, Md Aftab Alam, Mohd Amir, Abuzer Ali

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 98 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Effect of naringenin based nanocomposites and pure naringenin on cumin (Physiology and molecular biology of plants : an international journal of functional plant biology · 2024
    Article
  8. Main Aspects of Pharmaceutical Development ofCurrent pharmaceutical biotechnology · 2024
    Review
  9. Naringenin Nanoformulations for Neurodegenerative Diseases.Current pharmaceutical biotechnology · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Niyaz AhmadDepartment of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Rizwan AhmadDepartment of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Farhan Jalees AhmadNanomedicine Lab, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India.
Wasim AhmadDepartment of Pharmacy, Mohammad Al-Mana College for Medical Sciences, Safaa, Dammam-34222, Saudi Arabia.
Md Aftab AlamDepartment of Pharmaceutics, School of Medical and Allied Sciences, Galgotias University, Gautam Budh Nagar, Greater Noida 201310, India.
Mohd AmirDepartment of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Abuzer AliCollege of Pharmacy, Taif University, Taif 21974, Saudi Arabia.
Imam Abdulrahman Bin Faisal University · SAGalgotias University · INJamia Hamdard · INTaif University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHere, the aim is to improve the bioavailability of Naringenin (NRG) in brain and to establish the highest remedial benefit from a novel anti-ischemic medicine i.e. NRG.

methodsA novel Naringenin-loaded-nanoemulsion (NE)-(

resultsThe mucoadhesive potency and gelling temperature of NRG-NE-gel + 0.50%CS were observed 6245.38 dynes/cm

conclusionIntranasally administered NRG-NE-gel + 0.50%CS enhanced the bioavailability of Naringenin in the brain. In the cerebral ischemic rats, significantly improved the neurobehavioral activity (locomotor & grip strength) followed by antioxidant activity as well as infarction volume. Finally, the toxicity studies carried out and established the safe nature of optimized-NRG-NE-gel + 0.50%CS.

Indexed as

ANOVA., analysis of varianceAUC, area under curveBA, bioavailabilityCerebral ischemiaCLSM, confocal laser scanning microscopyCmax, maximum plasma concentrationCS, chitosanESI, electrospray ionizationHQC, high quality controlKel, elimination rate constantLLE, liquid–liquid extractionLLOQ, lower limit of quantificationLLOQ QC, lower limit of quantification for quality controlLOD, lower limit of detectionLOQ, lower limit of quantitationLQC, low quality controlMCAO, middle cerebral artery occlusionMCAO-oxidative stressMQC, middle quality controlMucoadhesive-chitosan-based-nanoemulsion-gelNaringeninNE, nanoemulsionNRG, naringeninPDI, polydispersity indexPK, pharmacokineticQ-TOF, quadrupole time of flightSEM, scanning electron microscopet½, half-lifeTBARS, thiobarbituric acid reactive substancesTEM, transmission electron microscopeTmax, time to CmaxUHPLC-MS/MS-pharmacokineticUHPLC-MS/MS, ultra high performance liquid chromatography mass spectroscopy and mass spectroscopy

Identifiers

PMID31889876
PMCPMC6933235
OpenAlexW2991326441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.